Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

ReachMD CME

CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/case-application-unlocking-relapsedrefractory-myeloma-with-celmods/36574/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.